At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 205 enrolled
Drug / intervention
Vandetanib +1 moredrug
Likely dose
Vandetanib 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib
In Brief
A Phase 3 clinical trial evaluating Patient outreach and Vandetanib for Locally Advanced or Metastatic Medullary Thyroid Cancer and Medullary Thyroid Cancer. Completed, enrolled 205 participants across 66 sites in 20 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece, India, Israel, Italy, Poland, Russia, South Korea, Sweden, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartFeb 2011
Primary CompletionApr 2013
Study CompletionMar 2025
TodayJul 2026
First PostedFeb 17, 2011
Enrollment StartFeb 25, 2011
Primary CompletionApr 26, 2013
Study CompletionMar 13, 2025
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.4 years ago
Interventions
Patient outreachbehavioral
Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
Vandetanibdrug
Treatment 300mg vandetanib opel label.